Fig. 9

A hypothetical model of the mechanism of USP36 regulation of ERα signaling. The inhibition of USP36 decreases breast cancer progression via modulating ERα K48-linked deubiquitinating, which subsequently suppresses ERα signaling activity and tamoxifen resistance (draw by biorender)